| [1] |
Filippi M, Preziosa P, Langdon D, et al. Identifying progression in multiple sclerosis: New perspectives[J]. Ann Neurol, 2020, 88(3):438-452.doi:10.1002/ana.25808.
|
| [2] |
Shaw F, Chadwick C. The diagnostic utility of IgG index and oligoclonal bands for multiple sclerosis in a neurology hospital patient population[J]. Ann Clin Biochem, 2023, 60(5):353-355. doi:10.1177/00045632231179618.
|
| [3] |
中华医学会放射学分会磁共振学组, 中国医师协会神经内科医师分会. 多发性硬化MRI规范化应用专家共识[J]. 中华放射学杂志, 2023, 57(6):592-599. doi: 10.3760/cma.j.cn112149-20230404-00260.
|
| [4] |
Huppke B, Ellenberger D, Hummel H, et al. Association of obesity with multiple sclerosis risk and response to first-line disease modifying drugs in children[J]. JAMA Neurol, 2019, 76(10):1157-1165. doi: 10.1001/jamaneurol.2019.1997.
|
| [5] |
Koskderelioglu A, Gedizlioglu M, Eskut N, et al. Impact of chemerin, lipid profile, and insulin resistance on disease parameters in patients with multiple sclerosis[J]. Neurol Sci, 2021, 42(6):2471-2479.doi: 10.1007/s10072-020-04847-y.
pmid: 33097973
|
| [6] |
Huber JE, Chang Y, Meinl I, et al. Fingolimod profoundly reduces frequencies and alters subset composition of circulating T follicular helper cells in multiple sclerosis patients[J]. J Immunol, 2020, 204(5):1101-1110.doi: 10.4049/jimmunol.1900955.
pmid: 32034063
|
| [7] |
Sarıdaş F, Özpar R, Özdemir ÜF, et al. Relationship of cranial bone signal intensity to multiple sclerosis clinical course and progression[J]. Sci Prog, 2025, 108(2):368504251336090.doi:10.1177/00368504251336090.
|
| [8] |
Perriard G, Mathias A, Enz L, et al. Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes[J]. J Neuroinflammation, 2015, 12:119. doi: 10.1186/s12974-015-0335-3.
|
| [9] |
Montague T, Drummond J, Ng K, et al. Advancements in multiple sclerosis[J]. Intern Med J, 2025, 55(6):895-904.doi:10.1111/imj.70023.
pmid: 40171883
|
| [10] |
Akbayir E, Kizilay T, Erol R, et al. B-cell and T-cell populations in peripheral blood linked to ocrelizumab treatment efficacy in multiple sclerosis[J]. In Vivo, 2025, 39(2):1162-1172. doi:10.21873/invivo.13920.
pmid: 40010950
|
| [11] |
Vustraxv G, Yerdfpc J, Reatic M, et al. Blood biomarkers for multiple sclerosis:Neurofilament light chain and beyond[J]. EBioMedicine, 2024, 104:105214.doi:10.1016/j.ebiom.2024.105214.
|
| [12] |
Bar-Or A, Li R. Cellular immunology of relapsing multiple sclerosis: Interactions, checks, and balances[J]. Lancet Neurol, 2021, 20(6):470-483.doi:10.1016/S1474-4422(21)00063-6.
pmid: 33930317
|
| [13] |
Wong JK, Lin J, Kung NJ, et al. Cerebrospinal fluid immunoglobulins in primary progressive multiple sclerosis are pathogenic[J]. Brain, 2023, 146(5):1979-1992.doi:10.1093/brain/aawad031.
pmid: 36732292
|
| [14] |
Herranz E, Treaba CA, Barletta VT, et al. Characterization of cortico-meningeal translocator protein expression in multiple sclerosis[J]. Brain, 2024, 147(7):2566-2578.doi:10.1093/brain/awae030.
pmid: 38289855
|
| [15] |
Hochstetler A, Lehtinen MK. Choroid plexus as a mediator of CNS inflammation in multiple sclerosis[J]. Mult Scler, 2024, 30(5_suppl):19-23.doi:10.1177/13524585241292974.
|
| [16] |
Wicks TR, Shalaurova I, Wolska A, et al. Endogenous ketone bodies are associated with metabolic vulnerability and disability in multiple sclerosis[J]. Nutrients, 2025, 17(4):640.doi:10.3390/nu17040640.
|
| [17] |
DeLuca J. Fatigue in multiple sclerosis: Can we measure it and can we treat it?[J]. J Neurol, 2024, 271(9):6388-6392.doi:10.1007/s00415-024-12524-9.
pmid: 38967652
|
| [18] |
van Dam M, Krijnen EA, Nauta IM, et al. Identifying and understanding cognitive profiles in multiple sclerosis: A role for visuospatial memory functioning[J]. J Neurol, 2024, 271(5):2195-2206.doi:10.1007/s00415-024-12227-1.
pmid: 38409536
|
| [19] |
Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study[J]. Lancet, 2018, 391(10127):1263-1273.doi: 10.1016/S0140-6736(18)30475-6.
pmid: 29576505
|
| [20] |
Kapel-Reguła A, Du's-Ilnicka I, Radwan-Oczko M. Relevance of saliva analyses in terms of etiological factors, biomarkers, and indicators of disease course in patients with multiple sclerosis-A review[J]. Int J Mol Sci, 2024, 25(23):12559.doi:10.3390/ijms252312559.
|